FDA has learned that some ranitidine medicines, including some products commonly known as the brand-name Zantac, contain a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA—a known environmental contaminant and found in water and foods—is considered a probable human carcinogen. FDA has been investigating NDMA and other nitrosamine impurities in angiotensin II receptor blockers (ARBs) since last year. Read More
